Company: LENZ
Filing Date: 2025-11-05
Form Type: 10-Q
Source: 0001815776-25-000071
Chunk: 269

Company: LENZ Therapeutics, Inc.
Filing Date: 2025-11-05
Form: 10-Q
Item: Part II, Item 2
Chunk 269
---
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

There were no sales of unregistered securities by us during the quarter ended September 30, 2025 that were not previously reported in current reports on Form 8-K filed with the SEC.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

80

Table of Contents

Not applicable.

Item 5. Other Information

Securities Trading Plans of Directors and Executive Officers

On August 11, 2025, Evert Schimmelpennink, Chief Executive Officer of the Company, entered into a 10b5-1 trading plan intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act. This 10b5-1 trading plan provides for the sale of 225,000 shares of the Company’s common stock related to the exercise of option awards granted to Mr. Schimmelpennink. This 10b5-1 trading plan will become effective on January 19, 2026 and will terminate on June 30, 2026, subject to earlier termination as provided in the plan.

On August 12, 2025, Shawn Olsson, Chief Commercial Officer of the Company, entered into a 10b5-1 trading plan intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act. This 10b5-1 trading plan provides for the sale of 66,891 shares of the Company’s common stock related to the exercise of option awards granted to Mr. Olsson. This 10b5-1 trading plan will become effective on November 17, 2025 and will terminate on October 19, 2026, subject to earlier termination as provided in the plan.

During our last fiscal quarter, none of our other directors or officers, as defined in Rule 16a-1(f), adopted and/or terminated a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement,” as defined in Regulation S-K Item 408.

Item 6. Exhibits

ExhibitNumberDescription3.1Amended and Restated Certificate of Incorporation, as amended (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed with the SEC on March 22, 2024).3.2Amended and Restated Bylaws